Product Description
UCB4594 is an antibody targeting the immune checkpoint, human leukocyte antigen G, also known as HLA-G. (Sourced from: https://www.ucb.com/stories-media/Press-Releases/article/Cancer-Research-UK-Signs-Multi-Project-Collaboration-With-UCB-To-Advance-Oncology-Antibody-Candidates)
Mechanisms of Action: HLA-G Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cancer Research UK
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for UCB-4594](https://pryzm-maps.s3.us-west-2.amazonaws.com/75current_maps.png)
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Cancer|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CRUKD/24/001 | P2 |
Recruiting |
Ovarian Cancer|Colorectal Cancer|Gastrointestinal Cancer|Breast Cancer|Pancreatic Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Renal Cell Carcinoma|Esophageal Cancer|Cervical Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Stromal Tumors |
2029-11-01 |